Global environmental, social and economic challenges drive the need for new and improved solutions for food production and consumption. Food production within a sustainability corridor requires innovations exceeding traditional paradigms, acknowledging the complexity arising from sustainability. However, there is a lack of knowledge about how to direct further activities, to develop technologies as potential solutions for questions related to climate change, loss of soil fertility and biodiversity, scarcity of resources, and shortage of drinking water. One approach that promises to address these problems is controlled environment agriculture. Aquaponics (AP) combines two technologies: recirculation aquaculture systems (RAS) and hydroponics (plant production in water, without soil) in a closed-loop system. One challenge to the development of this technology is the conversion of the toxic ammonium produced by the fish into nitrate, via bacteria in a biofilter, to provide nitrogen to the plants. However, as this Special Issue shows, there are many other challenges that need to be addressed if the goal of the technology is to contribute to more sustainable food production systems.

No abstract

No abstract

No abstract

Abstract:International aquaponic production has increased over the past decade, but less is known about research activities and production facilities operating in Europe. We conducted an online survey to get a better idea about research and production in Europe, focusing on five areas of aquaponics (i.e., demographics, facilities used, fish and crops produced, funding sources, and personal or company priorities for further development). The 68 respondents were distributed among 21 European countries, 43% were working at a university, and 19% were commercial producers. Only 11.8% of those surveyed had sold fish or plants in the past 12 months. Most respondents were male (66.2%) and had a post-graduate degree (91.7%). Facilities were generally new (74.5% constructed after 2010) and self-designed. Production figures were modest, with less than 10 respondents producing more than 1000 kg of fish or plants per year (mostly tilapia or catfish and herbs or lettuce). Systems were often funded by government grants (35.3%). The great majority of respondents (80.4%) stated that aquaponics was not their main source of income. Most respondents prioritized using aquaponics for educational purposes, while few (25%) used it to produce their own food or improve their health. Questions related to personal knowledge about aquaponics underlined the need for more training about fish diseases and plant pests.

Background: Glecaprevir/pibrentasvir is a pangenotypic direct-acting antiviral regimen approved for treating adults chronically infected with hepatitis C virus (HCV).There are limited real-world data on glecaprevir/pibrentasvir to date.Aim: To evaluate the effectiveness and safety of glecaprevir/pibrentasvir under realworld conditions in the German Hepatitis C-Registry (DHC-R). Methods:The DHC-R is an ongoing, non-interventional, multicentre, prospective, observational cohort study that monitors patients with chronic HCV infection. Data were collected from patients who initiated glecaprevir/pibrentasvir and completed a screening visit on or after 2 August 2017. The primary effectiveness endpoint was sustained virological response at post-treatment Week 12 (SVR12). Safety and tolerability were also assessed. Results:As of 15 July 2018, 586 patients received glecaprevir/pibrentasvir and had documented SVR12 data, treatment discontinuation, loss to follow-up or HCV reinfection. Five hundred and fifty-two patients (94%) received on-label treatment. At baseline, most on-label patients were infected with HCV genotype 1 (53%) or 3 (33%), HCV treatment-naïve (90%), without cirrhosis (94%), and treated for 8 weeks (93%). Five hundred and thirty-four patients (96.7%) achieved SVR12 (intention-totreat [ITT] analysis). By modified ITT analysis (excluding patients who discontinued and did not achieve SVR12 or patients lost to follow-up), the SVR12 rate was 99.4% (n/N = 534/537). There was one documented virological failure (relapse) and two documented HCV reinfections. One hundred and forty-two (26%) adverse events (AEs) and 9 (2%) serious AEs occurred; 2 (<1%) AEs led to treatment discontinuation. All patients treated off-label (N = 34) achieved SVR12.Conclusion: Glecaprevir/pibrentasvir was highly effective and well tolerated under real-world conditions. Clinical trial number: DRKS00009717 (German Clinical Trials Register, DRKS).

Aquaponics is an approach of coupling two technologies: recirculation aquaculture (fish-farms) and hydroponics (soil-less cultivation of crops). While it is perceived as a way to contribute to more sustainable food systems, the technology is still in its infancy, with several challenges. This paper describes current conditions of development and identifies aspects that can promote or hinder future pathways. We focus our analysis on the EU, using Germany as an institutional case study, while also considering worldwide developments. We propose a framework to analyze aquaponics as an emerging technological innovation system at the interface between existing fish and plant production systems. The approach is explorative based on a literature review and interviews with experts. The main findings are that stakeholders have different views regarding the future development pathways, knowledge to manage complex systems in the long term is needed and it is still unclear how to design institutional conditions to deliver sustainable outcomes.

No abstract